NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

**Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

|  |
| --- |
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No. An issue was raised during consultation regarding the need to ensure that HER2 testing is accessible to all. However it was not suggested that specific a group currently has, or is at risk of having, unequal access. |

|  |
| --- |
| 1. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| The committee should ensure that recommendations do not differentially affect people of different groups. Potential equality issues surrounding access to HER2 testing should be kept in mind. |

|  |
| --- |
| 1. Has any change to the draft scope been agreed to highlight potential equality issues? |
| No |

|  |
| --- |
| 1. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| No |

**Approved by Associate Director (name):** …Richard Diaz … **Date:** 04/10/2023